KAWASAKI, Japan--(BUSINESS WIRE)--PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter “PeptiDream”)(Tokyo: 4587) today announced the ...
Peptidream Inc. has released promising results from preclinical testing of its oral myostatin inhibitors, administered in combination with semaglutide, in a mouse model of obesity.
Scholar Rock's apitegromab showed significant motor function improvements in SMA patients, achieving primary endpoints in the Phase 3 SAPPHIRE trial. Apitegromab's unique approach targets precursor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results